{
  "symbol": "MOBI",
  "company": "Mobia Medical, Inc.",
  "generated_at": "2026-06-24T07:36:29.134Z",
  "event_count": 1,
  "events": [
    {
      "type": "scout_dossier",
      "ts": "2026-05-12T08:37:30.687Z",
      "summary": "MOBI completed its IPO on May 11, 2026 at $15/share and began trading on Nasdaq Global Select Market. The stock immediately sold off ~20% to the ~$12 area as of current data (May 8-11 2026). The company is a commercial-stage medical device firm with one FDA-approved product — the Vivistim Paired VNS System for chronic ischemic stroke recovery — generating $32M in 2025 revenue (+105% YoY) but deeply unprofitable (-$46.5M net loss, -$29.4M FCF deficit). The insider cluster is real and concentrated: several directors and officers made open-market purchases at the $15 IPO price on May 11, 2026 (total ~$8-9M across multiple insiders), but this coincided with a company that had just gone public days earlier. These appear to be post-IPO participation buys rather than informed insider signals about intrinsic value divergence. No options chain exists yet (recently listed). The fundamental picture is mixed: strong 81% gross margins and rapid revenue growth are offset by no clear profitability path, ~$158M cumulative deficit, limited payor coverage for the device, and a thin public float (~3M shares out of 33M total). This is fundamentally a pre-profitability story in its first week as a public company — insufficient data on which to build any structured income or directional thesis.",
      "verdict": "no_anomaly",
      "confidence": 3,
      "tool_calls": 22,
      "walltime_min": 6,
      "debug_path": "dossiers/2026-05-12-MOBI.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "call": "NO_DATA",
    "confidence": 0,
    "score": 0,
    "factors": {},
    "summary": "insufficient bars (31)",
    "ticker": "MOBI"
  }
}